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http://www.molecular-cancer.com/content/11/1/35RESEARCH Open AccessThe isoflavone metabolite 6-methoxyequol
inhibits angiogenesis and suppresses
tumor growth
Sofia Bellou1,2, Evdoxia Karali2,6, Eleni Bagli2, Nawaf Al-Maharik3, Lucia Morbidelli4, Marina Ziche4,
Herman Adlercreutz5, Carol Murphy2 and Theodore Fotsis2,6*Abstract
Background: Increased consumption of plant-based diets has been linked to the presence of certain
phytochemicals, including polyphenols such as flavonoids. Several of these compounds exert their protective effect
via inhibition of tumor angiogenesis. Identification of additional phytochemicals with potential antiangiogenic
activity is important not only for understanding the mechanism of the preventive effect, but also for developing
novel therapeutic interventions.
Results: In an attempt to identify phytochemicals contributing to the well-documented preventive effect of
plant-based diets on cancer incidence and mortality, we have screened a set of hitherto untested phytoestrogen
metabolites concerning their anti-angiogenic effect, using endothelial cell proliferation as an end point. Here, we
show that a novel phytoestrogen, 6-methoxyequol (6-ME), inhibited VEGF-induced proliferation of human umbilical
vein endothelial cells (HUVE) cells, whereas VEGF-induced migration and survival of HUVE cells remained unaffected.
In addition, 6-ME inhibited FGF-2-induced proliferation of bovine brain capillary endothelial (BBCE) cells. In line with
its role in cell proliferation, 6-ME inhibited VEGF-induced phosphorylation of ERK1/2 MAPK, the key cascade
responsible for VEGF-induced proliferation of endothelial cells. In this context, 6-ME inhibited in a dose dependent
manner the phosphorylation of MEK1/2, the only known upstream activator of ERK1/2. 6-ME did not alter VEGF-
induced phosphorylation of p38 MAPK or AKT, compatible with the lack of effect on VEGF-induced migration and
survival of endothelial cells. Peri-tumor injection of 6-ME in A-431 xenograft tumors resulted in reduced tumor
growth with suppressed neovasularization compared to vehicle controls (P< 0.01).
Conclusions: 6-ME inhibits VEGF- and FGF2-induced proliferation of ECs by targeting the phosphorylation of MEK1/
2 and it downstream substrate ERK1/2, both key components of the mitogenic MAPK pathway. Injection of 6-ME in
mouse A-431 xenograft tumors results to tumors with decreased neovascularization and reduced tumor volume
suggesting that 6-ME may be developed to a novel anti-angiogenic agent in cancer treatment.
Keywords: Angiogenesis, VEGF, Phytoestrogen, MAPK, A-431 xenograft* Correspondence: thfotsis@uoi.gr
2Department of Biomedical Research, Foundation of Research and
Technology-Hellas, Institute of Molecular Biology & Biotechnology, University
Campus, 45110, Ioannina, Greece
6Laboratory of Biological Chemistry, Medical School, University of Ioannina,
45110, Ioannina, Greece
Full list of author information is available at the end of the article
© 2012 Bellou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Bellou et al. Molecular Cancer 2012, 11:35 Page 2 of 11
http://www.molecular-cancer.com/content/11/1/35Introduction
Physiological angiogenesis is a strictly regulated fine-
tuned process. The local balance between inducers and
inhibitors of angiogenesis is critical in determining the
generation or not of new vessels. Whenever this balance
is perturbed pathological, uncontrolled, excessive angio-
genesis occurs. Psoriasis, rheumatic arthritis and diabetic
retinopathy constitute some of the diseases in which
pathological angiogenesis contributes to their pathogen-
esis. However, tumor angiogenesis is the most striking
manifestation of abnormal angiogenesis. Indeed, it has
been demonstrated that formation of new blood vessels is
required for tumor growth beyond a diameter of 1-2 mm.
Vascular endothelial growth factor A (VEGFA), also
referred to as VEGF, represents a critical inducer of
tumor angiogenesis and is the first-choice target of anti-
angiogenic therapies tested in clinical trials [1]. VEGF
belongs to a subfamily of secreted, dimeric glycoproteins
of approximately 40 kDa, which in turn belongs to the
platelet-derived growth factor (PDGF) superfamily. In
mammals, VEGF family consists of VEGF-A, B, C, D
and placental growth factor 1 and 2 (PlGF1 and 2). Spe-
cifically VEGF exists as multiple isoforms, resulting from
alternative splicing. The most predominant isoform is
VEGF165 (a 165-amino acid protein), which is over-
expressed in a variety of human solid tumors [2,3]. All
VEGF molecules/ligands transduce their signal through
their binding to VEGF receptor −1, -2 and −3. However,
VEGFR-2 is the key molecule for VEGF signaling in the
tumor micro-environment including vascular permeabil-
ity and endothelial cell proliferation[2,4]. Several cas-
cades emanating from the VEGF/VEGFR2 complex
regulate critical angiogenic responses of endothelial cells.
Endothelial cell proliferation is regulated by activation of
PLCγ, a SH2-domain-containing molecule that interacts
directly with activated VEGFR-2 and mediates the phos-
phorylation of mitogen-activated protein kinase (MAPK)/
extracellular – signal-regulated kinase 1/2 (ERK1/2) cas-
cade [5]. VEGF enhances survival of endothelial cells
using the PI3K/AKT pathway, whereas it stimulates endo-
thelial cell migration through p38 MAPK phosphorylation
[6]. Signaling cascades of the VEGF/VEGFR2 complex
result in the expression of dual specificity phosphatases
(DUSP) 1 & 5, which dephosphorylate and inactivate
MAPKs, functioning as an auto-regulatory circuit [7].
Consumption of plant-derived diets exerts a preventive
effect on cancer incidence in humans. Several dietary phy-
tochemicals exhibit anti-mitotic and/or anti-angiogenic
activity mediating the protective effect of vegetarian diets
on cancer. In this context, we have demonstrated that
the isoflavonoid genistein is a potent inhibitor of tumor
cell proliferation and angiogenesis [8]. Subsequently, we
have shown that several of the isomeric flavonoids exhib-
ited similar anti-angiogenic activity as genistein [9]. Inparticular, luteolin inhibited VEGF-induced angiogenesis by
targeting VEGF/VEGFR2-induced PI3K activity. Detailed
elucidation of the mechanism demonstrated that luteolin
compromised VEGF-induced survival of HUVECs via
blockage of PI3K/Akt-dependent pathways, whereas
inhibition of the PI3K/p70 S6K pathway mediated the
anti-mitotic effects of the compound on HUVECS [10].
In the present study, we have screened additional iso-
flavonoids for anti-angiogenic activity and identified that
6-methoxyequol inhibits VEGF-induced MEK1/2 phos-
phorylation and endothelial cell proliferation leaving
unaffected the migratory and survival functions of VEGF.
Treatment of xenograft A-431 tumors in mice using
oral administration of 6-ME failed to reduce the volumes
of the tumors, because the compound failed to achieve
sufficient plasma levels as documented using an HPLC-
CEAD method. However, injecting directly 6-ME to the
xenograft tumors, to bypass the low bioavailability, result-
ing in a statistically significant reduction of tumor volume
compared to controls and suppressed vascularization.
Materials and methods
Antibodies and chemicals
Human VEGF165 was purchased from ImmunoTools
(ImmunoTools GmbH, Friesoythe, Germany). Rabbit
polyclonal anti-phospho-p38, anti-ERK1/2, anti-phospho-
ERK1/2, anti-phospho-Akt and anti-Akt antibodies were
obtained from Cell Signaling (Cell Signaling Technology,
Inc, Beverley, MA). Anti-BrdU was from Sigma (Sigma,
St. Louis, MO). All secondary antibodies were pur-
chased from Jackson ImmunoResearch Europe Ltd, UK.
CycleTEST PLUS DNA Reagent kit was from Becton
Dickinson Biosciences.
Cell culture
Human endothelial cells from umbilical vein (HUVEC)
were plated on dishes pre-coated with rat collagen type I
(Becton Dickinson Biosciences) and cultured in M199
medium supplemented with 20% fetal calf serum (FCS),
50 micrograms/ml endothelial cell growth supplement
(ECGS, Sigma), heparin 10u/μl (Sigma) and 1% penicil-
lin-streptomycin. All media and sera for cell culture
were purchased from Invitrogen and were endotoxin-
free. 6-methoxyequol was tested for endotoxin content
using the QCL1000 kit from BioWhittaker, Inc. For all
experiments 6-methoxyequol was resuspended in DMSO/
ethanol, 1/1 by volume, and added directly to the culture
medium. Cells not receiving 6-methoxyequol were incu-
bated in the corresponding volume of DMSO/ethanol.
Primary cell growth assay
Primary bovine brain capillary endothelial (BBCE) cells
were split into 12-well dishes at 5,000 cells per well and
24 h later cell stimulated with FGF2 (2.5 ng/ml) in the
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trations. After 2 days, cells were again stimulated or not
by FGF2 in the absence or presence of 6-methoxyequol
and the next day cells were counted.
Cancer cell growth assay
Hela, LnCAP, T24 (Human bladder carcinoma) or MCF7
(Human breast adenocarcinoma) cancer cells were split
into 12-well plates either at 5,000, in case of Hela, T24
and MCF7 or at 20,000 in case of LnCAP, cells per well
and 24 h later cells were treated or not with various con-
centrations of 6-methoxyequol. After 2 days, cells were
again treated or not with 6- methoxyequol and the next
day cells were counted.
Apoptosis assay
For analysis by flow cytometry, HUVECs were serum
starved for 6 h in medium containing 5% FCS and trea-
ted with VEGF (50 ng/ml) for 18 h in the presence or
absence of 6-methoxyequol (10 μM) for the same period
of time. At the end of the incubation time, floating and
adherent cells were collected in ice-cold PBS, stained
with propidium iodine using the CycleTEST PLUS DNA
Reagent kit and processed for flow cytometric analysis
using a Becton Dickinson Fluorescence Activated Cell
Scanner (FACS). The percentage of cells with sub-G1
DNA content was considered as the cell population that
had undergone apoptosis.
Proliferation assay (BrdU incorporation)
HUVECs were grown on collagen-coated coverslips and
serum starved in medium containing 5% FCS, 1% pen/
strep and heparin for 18 h. Cells were induced with
VEGF (50 ng/ml) in the absence or presence of various
concentrations of 6-methoxyequol for 24 h. Bromodeox-
yuridine (BrdU; Sigma, St. Louis, MO) was added 6 h
before the VEGF-induction was complete. Cells were
fixed in 3.7% paraformaldehyde, quenched with 50 mM
ammonium chloride for 15 min, permeabilized with 0.1%
Triton X-100 for 4 min, and non-specific sites were blocked
with fetal serum. The proliferating cells were detected
with an anti-BrdU antibody. Coverslips were mounted in
Mowiol and viewed using Leica DM IBRE microscope.
Cell migration assay
Confluent HUVE cell monolayers were wounded with
a sterile plastic pipette tip, cultured in M199 medium sup-
plemented with 5% FCS and induced with VEGF (10 ng/
ml) in the presence or absence of 6-methoxyequol (10 μM).
Cells were placed in a 37°C, 5% CO2 chamber and moni-
tored using a Leica DM IBRE microscope equipped with a
HRD060-NIK CCD-camera (Diagnostic Instruments, Ster-
ling Heights, MI, USA) and metamorph software. Frames
were taken every 10 min for 16 h. Results were expressed
as number of cells per centimetre of wound.Tube formation assay
Matrigel was thawed on ice overnight and spread evenly
over each well (500 μl) of a 24-well plate. The plates
were incubated for 30 min at 37°C to allow the matrigel
to polymerize. HUVECs were seeded on coated plated at
4 x 104cells/well in M199 supplemented with 5% FCS in
the presence or absence of 6-methoxyequol at various con-
centrations (1-50μM). Plates were incubated for 12 h at 37°
C. Tube formation was observed using an inverted phase
contrast microscope (Zeiss Axiovert S-100; Germany).
Phosphorylation of MAP kinases
HUVECs were cultured in M199 supplemented with
20%FCS, ECGS, heparin & pen/strep until 80% conflu-
ence. Cells were serum starved for 2 h in medium con-
taining 0% FCS and then treated with VEGF (50 ng/ml)
in the presence or absence of either 6-methoxyequol
(1,5,or 10μM) or DMSO for 15 min. Cells were washed
with ice-cold PBS and lysed in lysis buffer (1% SDS
supplemented with protease and phosphatase inhi-
bitors). The lysates were resuspended in Laemmli buffer,
subjected to SDS-PAGE and blotted onto a nitrocellu-
lose membrane. Phosphorylated ERK1/2 and p38 were
detected using specific rabbit polyclonal antibodies and
an anti-rabbit peroxidase-conjugated secondary antibody,
followed by detection using a chemiluminescence-based
system. The membranes were then stripped and reprobed
with antibodies against ERK1/2 and p38 to normalize the
phosphorylation data against expression of the kinases.
qRT-PCR experiment
Quantitative Reverse Transcription-PCR (qRT-PCR)
experiments were performed using The LightCyclerW 2.0
Instrument (Roche Diagnostics GmbH, Mannheim,
Germany) and QuantiTect SYBR Green RT-PCR Kit
(Qiagen, GmbH, Germany). Total RNA was isolated
after 15 and 30 min treatment with VEGF (50 ng/ml) in
the absence or presence of 6- methoxyequol (10μM).
Synthesis of 6-methoxyequol
To test 6-ME in animal models considerably larger
quantities were required. Since, this compound is not
commercially available we undertook its synthesis as
described in detail in the Additional file 1. In brief, start-
ing from 6-methoxyresorcinol and 4-hydroxyphenylacetic
acid the desired deoxybenzoin was first obtained in 48%
yield. Treatment of the deoxybenzoin with N,N-
dimethylformamid (DMF) in the presence of methane-
sulfonyl chloride at 70°C generated glycitein, which was
hydrogenated using 10% Pd/C to 6-methoxyequol in
high yield and purity. A detailed analysis of 1-(2,4-
dihydroxy-5-methoxyphenyl)-2-(4’-hydroxyphenyl) etha-
none, 7,4’-Dihydroxy-6-methoxyisoflavone (Glycitein) and
7,4’-Dihydroxy-6-methoxyisoflavane synthesis is described in.
Table 1 IC50 list of isoflavonoids tested on endothelial
cell proliferation
Compound IC50(μM)
1 3’,8-Dinitro-7-hydroxy-4-methoxyisoflavone >50
2 7-Hydroxy-4-methoxy-3’,5’,8-trinitroisoflavone 45.9
3 4,7-Dihydroxy-3’,5’,8-trinitroisoflavone >50
4 3’-Nitro-2,4,4’-trihydroxydeoxybenzoin >50
5 2,4-Dihydroxy-4’-methoxy-5-nitrodeoxybenzion >50
6 5,7-Dihydroxy-4’-nitroisoflavone 14.1
7 7-Hydroxy-4’-methoxy-8-nitroisoflavone >50
8 3’-Nitro-5,7,4’-trihydroxyisoflavone 35.2
9 7,4’-Dihydroxy-3’-nitroisoflavone 42.3
10 5,7-Dihydroxy-2’-methyl-4’-nitroisoflavone 19.5
11 8,4’-Dinitro-7-hydroxyisoflavone >50
12 4’-Amino-5,7-dihydroxyisoflavone >50
13 8’-Amino-7-hydroxy-4’-methoxyisoflavone 31.7
14 3’-Amino-5,7,4’-trihydroxyisoflavone 24.8
15 3’-Amino-7,4’-dihydroxyisoflavone 37.5
16 4’-Amino-5,7-dihydroxy-2’-methylisoflavone >50
17 4’,8-Diamino-7-hydroxyisoflavone >50
18 8,4’-Diamino-7,5,dihydroxyisoflavone >50
19 7,4’-Dihydroxy-8,5’-dinitroisoflavone 42.2
20 4’-methylequol 28
21 3’-methoxyequol 19
22 6-methoxyequol 3
23 6’-OH-ODMA 38
24 4’-O-methylequol 25
25 7’-Hydroxyenterolactone >50
26 Pinoresinol 38
27 Luteolin 5
28 Genistein 5
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To assess the in vivo anti-angiogenic/anti-tumor activity of
6-methoxyequol, female immunodeficient mice (5–8 week-
old BALB/c nude mice, Charles River, Milan, Italy), kept
with ad libitum water and Protein Rodent Maintenance
Diet (Harlan n. 2014), were inoculated subcutaneously in
the right flank with 107 A-431 cells in a volume of 50 μl
(Morbidelli et al., Clinic Cancer Res, 2003; Bagli et. al.,
Cancer Res, 2004). After 9 days, when tumors reached a
volume of 170 mm3, animals were randomly assigned to
2 different experimental groups (9–10 mice per group).
Peri-tumor treatment with 6-methoxyequol (5 μg/day/
mice) or vehicle then began. The local peri-tumor treat-
ment was performed at the dose of 5 μg/50 μl/mouse/day.
The vehicle containing the same concentrations of solvents
(1% ethanol + 1% DMSO) was used as control. Daily treat-
ment was performed for 10 consecutive days. Serial caliper
measurements of perpendicular diameters were used to
calculate tumor volume using the following formula:
(shortest diameter x longest diameter x thickness of the
tumor in mm). Data are reported as tumor volume in
mm3. Experiments have been performed in accordance
with the guidelines of the European Economic Community
for animal care and welfare (EEC Law No. 86/609) and Na-
tional Ethical Committee. Animals were observed daily for
signs of cytotoxicity and were sacrificed by CO2 asphyxi-
ation. At day 10 animals were sacrificed and each tumor
was immediately frozen in liquid nitrogen. 7 μm-thick
cryostat sections were stained with hematoxylin and eosin
and adjacent sections were used for immunohistochemical
staining with the anti-ED-B monoclonal antibody after fix-
ation in absolute cold acetone.
In the set of mice treated orally with 6-ME, the com-
pound was firstly dissolved in 50% ethanol and 50%
DMSO and then diluted with extra pure olive oil (final
0,25% ethanol and 0,25% DMSO). We have used as ve-
hicle olive oil with the same amount of solvents. The daily
dose of 6-ME was 100 mg/kg administered by lavage
(200 μl/mouse). Treatment started when tumors were
palpable and continued until day 11, the day of sacrifice.
To accesses 6-ME bioavailability in mice, we determined
6-ME in urine and plasma as described in Additional file 1.
Results
Screening of flavonoids revealed that 6-methoxyequol is
a specific inhibitor of endothelial cell proliferation
exhibiting minor anti-mitotic effect on tumor cells
We screened a selection of isoflavonoids on endothelial
cell proliferation seeking to identify additional structures
with antiangiogenic activity compared to that of genistein.
From the 28 isoflavonoids tested, only 6-methoxyequol
(6-ME) had a strong inhibitory effect on FGF2-induced
endothelial cell (BBCE) proliferation exhibiting an IC50 of
approximately 3 μM (Table 1 and Figure 1A), slightlylower than that of genistein and luteolin (IC50 around
5μM) [9,10]. The antimitotic effect of 6-methoxyequol
appeared to be specific to endothelial cells as 6-ME was
devoid of any antimitotic effect on 4 different cancer cell
lines at a concentration of 6.25μM, even though at higher
doses an inhibitory/toxic effect could be observed
(Figure 1B). Moreover, 6-ME did not affect proliferation
of human fibroblasts even at 20μM concentration
(Additional file 1: Figure 1A and B). The inhibitory effect
of 6-ME on endothelial cells was consistent as it inhibited
also VEGF-induced proliferation of HUVECs (Figure 1C).
6-methoxyequol does not influence VEGF-induced
survival of endothelial cells
To exclude an inhibitory (apoptotic) effect of 6-ME on
VEGF-induced survival of endothelial cells, we tested
the effect of 6-ME on VEGF-treated endothelial cells fol-
lowing serum starvation. Withdrawal of serum is well
known to induce endothelial cell apoptosis, which is
Figure 1 Effect of 6-ME on endothelial and cancer cell
proliferation. (A) BBCE cells were seeded 24 h before stimulation
by FGF (2.5 ng/ml) in the absence or presence of different
concentrations of 6-ME. After 48 h cells were again stimulated with
FGF (2.5 ng/ml) in the absence or presence of 6-ME and next day
cells were counted. (B) HeLA, LnCAP, MCF7 or T24 cells were treated
or not with various concentrations of 6-ME. After 48 h 6-ME was
added again and 24 h later cells were counted. (C) HUVE cells were
serum starved for 6 h in 5% FBS M199 supplemented with heparin
and pen/strep. Then cells were stimulated by VEGF (50 ng/ml) for
18 h in the absence or presence of various concentrations of 6-ME.
BrdU was added 6 h before the VEGF-induction was complete. Then
indirect immunoflourescence was performed and the cells were
viewed using Leica IBRE microscope. Graph indicates percentage of
BrdU-incorporated cells ± s.d. derived from four independent
experiments. ***p< 0.0001, **p = 0.0013, *p = 0.0056.
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HUVECs were apoptotic, being hypodiploid in FACS
analysis, after serum starvation (in 5% FCS) (Figure 2Ai),
treatment with VEGF for 18 h rescued almost 50% (6%
apoptotic cells) of the cells from apoptosis (Figure 2Aii).
Upon treatment of serum deprived HUVECs with10 μM concentration of 6-ME, 11.5% of HUVECs were
apoptotic (Figure 2Aiii) showing no difference to the
DMSO control (11% in Figure 2Ai). Finally, treatment of
serum starved HUVECs with 10 μM of 6-ME did not
affect the VEGF-induced survival of endothelial cells
(4.1% apoptotic cells in Figure 2Aiv). The above observa-
tions were further confirmed using Annexin/PI-apoptosis
assay (Additional file1: Figure S2). These results strongly
suggested that 6-ME had no effect on the survival cas-
cades of VEGF.
6-methoxyequol does not inhibit migration of endothelial
cells and tube formation in vitro
Next, we investigated the possibility that 6-ME could in-
hibit other processes of angiogenesis. Indeed, angiogen-
esis is a complex process requiring the coordinated,
sequential involvement of a number of cellular events.
Formation of new capillaries begins with a localized
breakdown of the basement membrane of the parent
vessel, followed by migration of endothelial cells for
invasion of the surrounding matrix. There, a cell-matrix
mediated outgrowth of an endothelial tip cell is followed
by stalk cell proliferation and eventually by tube forma-
tion with an encased lumen sealed by tight cell-cell junc-
tions. The endothelial cell migration assay and the
in vitro angiogenesis assay on Matrigel recapitulate rea-
sonably well these early events of angiogenesis. 6-ME, at
10 μM concentration, did not influence the VEGF-
induced migration of endothelial cells in wounded conflu-
ent monolayers of HUVECs (Figure 2B). Similarly, 6-ME,
even at 50 μM concentration, did not perturb capillary-
like tube formation of HUVECs plated on Matrigel
(Figure 2C) or the structure of the cytoskeleton (Add-
itional file1: Figure S3). Thus, 6-ME appears to affect
only endothelial cell proliferation leaving unaffected
other angiogenic responses of endothelial cells.
6-methoxyequol inhibits activation of the MEK1/2-ERK1/2
pathway by VEGF
Having established that 6-ME inhibits only endothelial
cell proliferation without affecting survival, migration
and tube formation, we sought mechanistic confirmation
of these findings. Indeed, 6-ME did not affect VEGF-
induced phosphorylation of AKT (Figure 2D, upper
panel), one of the key cascades that confer endothelial
cell survival [11]. Likewise, 6-ME did not affect VEGF-
induced phosphorylation of p38 MAPK (Figure 2D,
lower panel), a signaling cascade that mediates the
induction of endothelial cell migration by VEGF [12].
These results, together with the fact that 6-ME does
not inhibit PLC-γ activation, as VEGF-induced calcium
release in not affected (Additional file1: Figure 4),
exclude the kinase activity of VEGFR2/KDR of being the
target of 6-ME. In confirmation, 6-ME clearly inhibited,
Figure 2 Effect of 6-ME on VEGF-induced survival, migration of endothelial cells and tube formation in vitro and phosphorylation of
Akt and p38 MAPK. (A) HUVE cells were serum starved in 5% FBS M199 supplemented with heparin and pen/strep. Then cells were stimulated
or not with VEGF (50 ng/ml) in the presence or absence of 6-ME (10μM) for 18 h. Floating and adherent cells were analyzed by flow cytometry.
The number indicates the percentage of the hypodiploid cells. The experiment shown is a representative one from three independent
experiments. (B) Confluent HUVE cell monolayers were wounded with a sterile tip prior to serum-starvation in M199 supplemented with 5% FBS,
heparin and pen/strep. Then, cells were induced by VEGF (50 ng/ml) in the presence or absence of 6-ME (10μM) and placed in a 37°C, 5% CO2
chamber and monitored using a Leica DM IBRE microscope equipped with a HRD060-NIK CCD-camera and metamorph software. The graph
shows images taken from non-induced cells at time points 0 and 600 min (at 600 min we have the possibility of contribution from proliferation –
I would show an earlier time point) and from induced cells at the same time points, in the presence or absence of 6-ME, representing the
number of the cells per centimeter of wound± s.d. derived from three independent experiments. (C) HUVE cells were seeded on polymerized
matrigel in M199 supplemented with 5% FBS, 1% pen/strep and heparin at density 8 x 104 cell/ml. Then cells were treated with DMSO or 6-ME
at various concentrations for 12 h and tube formation was observed using an inverted microscope. (D) HUVE cells were serum starved for 2 h in
M199 and then stimulated with VEGF (50 ng/ml), in the absence or presence of 6-ME, for 15 min. Then cell lysates were collected with 1% SDS
lysis buffer, supplemented with PMSF, and immunoblotting followed using antibodies against endogenous phospho-Akt, actin, phospho-p38
and p38. Experiments shown in (A) and (B) are representative from three independent experiments.
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(Figure 3A) and its downstream target ERK1/2 (Figure 3B),
components of the mitotic MAPK pathway that VEGF
triggers via PLC-γ activation. Several growth factors acti-
vate the ERK1/2 MAPK pathway in a Ras-dependent
manner [13,14]. Indeed, 6-ME inhibited also FGF2-
induced phosphorylation of ERK1/2 fully compatible
with the fact that 6-ME inhibited also FGF2-induced
proliferation of BBCE cells (Figure 1A). To fully confirm
inhibition of the ERK1/2 cascade by 6-ME, we sought
additional evidence by investigating the transcriptional
activation of DUSP1 and DUSP5 genes that are regulated
by VEGF via the ERK1/2 pathway [15-18]. DUSP1 and
DUSP5 are dual-specificity phosphatases that depho-
sphorylate ERK1/2 and p38 MAPK, being part of an
auto-regulatory circuit [7]. Indeed, 6-ME clearly inhibited
the induction of DUSP1 and DUSP5 mRNA levels by
VEGF (Figure 3D) leaving no doubt that it inhibits
VEGF-induced ERK1/2 activation.
6-methoxyequol inhibits xenograft tumor growth only
when administered directly to the tumors
Next, we undertook the task of testing the compound
in mouse xenograft tumor models. For this purpose, theFigure 3 Effect of 6-ME on VEGF-induced phosphorylation of MEK1/2
were serum starved for 2 h in M199 and then stimulated with VEGF (50 ng
ME, for 15 min. Then cell lysates were collected with 1% SDS lysis buffer su
antibodies against endogenous phospho-MEK1/2, MEK1/2, phospho-ERK1/2
derived from three independent experiments. (D) HUVE cells were stimulat
for 30 min. Then, total RNA was isolated and qRT-PCR experiments followesynthesis of sufficient quantities of 6-ME was assured
using acylation of 4-methoxyresorcinol with 4-hydroxy-
phenylacetic, followed by treatment of the resulting
deoxybenzoin with N,N-dimethylformamid to yield glyci-
tein, which was hydrogenated to 6-methoxyequol in high
yield and purity (Additional file1).
We used a murine tumor xenograft model utilizing A-
431 cells, a human epidermoid carcinoma cell line that
produces VEGF [19]. Since in previous studies we and
others have found that isoflavonoids may exhibit low
bioavailability [20,21], we decided to carry out two
sets of experiments. In one set, 6-ME was administered
orally in olive oil suspension whereas in the other, the
compound was injected directly in the vicinity of the
xenograft tumor.
6-ME administered orally in this model was devoid of
any effect. The experimental and control tumors did not
show any difference in their average volumes (Figure 4A)
even though some of the experimental tumors were
clearly smaller in volume compared to the control
tumors (data not shown). We postulated that low bio-
availability is the reason for the lack of effect. Indeed,
estimation of the free, conjugated and total amounts
of 6-ME in the plasma of the mice revealed thatand ERK1/2 and transcription of DUSP1 and DUSP5. HUVE cells
/ml) (A & B) or FGF (2.5 ng/ml) (C), in the absence or presence of 6-
pplemented with PMSF and immunoblotting followed using
, ERK1/2 and actin. Graphs show normalized intensity values ± s.d.
ed by VEGF (50 ng/ml) in the absence or presence of 6-ME (20, 10μM)
d using primers for DUSP1 and DUSP5.
Figure 4 In vivo experiments. Female immunodeficient mice were inoculated subcutaneously in the right flank with 107 A-431 cells in a
volume of 50 μl. When tumors reached a volume of 100 mm3 (A & B) or 170 mm3 (C & D), animals were randomly assigned to 2 different
experimental groups and oral or peri-tumor treatment with 6-ME (5 μg/day/mice) or vehicle began, according to Materials and Methods. (A)
Graph shows the tumor volume (mm3) ± s.d. derived from 9 animals. (B) Free fraction (Free fr), conjugated fraction (Conj fr) and total amount of
6-ME in the plasma of 9 animals (m1-m9) (C) Graph shows the tumor volume (mm3) ± s.d. derived from 9 animals in the case of 6-ME treated
mice and 4 animals treated with vehicle, since the increased tumor volume and ulceration started from day 6 caused the death of 5 animals in
this group. (D) The effect of 5 ug/day 6-ME (panels iii-iv) on tumor angiogenesis at day 10 was compared to vehicle treated group (panels i-ii).
Representative pictures of tumor sections stained with hematoxylin and eosin (i,iii) and with the antibody specific for B-FN (ii,iv).
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(Figure 4B), a value below the in vitro IC50 of the com-
pound (around 5-10μM).
Injecting directly the A-431 tumors with 6-ME (5 μg/
day/mice) reduced the growth of tumors compared to the
control group treated with vehicle. Tumors in 6-methox-
yequol treated mice were significantly smaller (approxi-
mately 50%, P< 0.01 vs. vehicle group at day 6 and 8)
than in control mice beginning from day 2 (Figure 4C).
B-fibronectin (B-FN), the fibronectin (FN) isoform con-
taining extradomain B (ED-B) accumulates around neo-
vascular structures in aggressive tumors and other tissues
undergoing angiogenesis and remodeling [22]. The mono-
clonal anti-ED-B antibody against the ED-B domain
in fibronectin [23] indicated the presence of tumor vas-
culature in tumors of the control group, which was
absent in 6-methoxyequol treated tumors (Figure 4D).
Regarding the survival, at day 8 mice survival was 78% in
the 6- methoxyequol group and 44% in the vehicle group.
Discussion
In previous studies, we have demonstrated that the iso-
flavonoid genistein is an angiogenesis inhibitor [8].
In the present study, we have screened a number of
hitherto untested isoflavonoids using inhibition of ECproliferation as an indicator of possible anti-angiogenic
activity. Only, 6-ME inhibited EC proliferation with an
IC50 comparable to that of genistein or the flavonoid
Luteolin (around 5 μM). Interestingly, 6-ME inhibited
both VEGF- and FGF2-induced proliferation of endothe-
lial cells, whereas it had no effect on the serum-induced
proliferation of four cancer cell lines. Apparently, 6-ME
exhibits certain selectivity towards inhibition of EC prolif-
eration. 6-ME is an isoflavan metabolite that has been
identified in human urine following soy or red clover sup-
plementation [20,21,24,25]. However, only trace amounts
of 6-ME are excreted in human urine. 6-ME originates
from glycitein; the amount of the original substance is
low in soy compared to daidzein and genistein, that may
explain the low amounts of the metabolite [24].
Though 6-ME inhibited both VEGF- and FGF2-induced
proliferation of ECs, we decided to study the effects of
6-ME only on VEGF-dependent EC responses, because
VEGF is the most important mediator of tumor angio-
genesis. Indeed, cancer cells over-express VEGF either
following hypoxia or as a consequence of the genetic
changes of cancer such as mutations of oncogenes and
tumor suppressor genes [26]. In fact, endothelial cells
adjacent to the tumor vessels over-express VEGFR-1
and −2 [27] establishing an angiogenic loop.
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in the proliferation assay derived from a truly cytostatic
effect (cell cycle inhibition) of 6-ME or was the result
of cytotoxicity/apoptosis, we further investigated the
effect of the compound on the VEGF-induced survival of
endothelial cells. 6-ME, administered alone to endothelial
cell cultures did not increase the percentage of apoptotic
cells compared to solvent-treated cultures. Moreover,
6-ME administered together with VEGF did not have any
influence on the VEGF-induced rescue of apoptosis. This
result, in other words, indicated that 6-ME did not inhibit
the EC survival signaling cascades emanating from the
active VEGF/VEGFR2 complex. In confirmation, 6-ME
did not inhibit VEGF-induced phosphorylation of AKT,
an important component of the PI3K signaling pathway,
the main anti-apoptotic cascade in most cells.
Having established that 6-ME inhibits endothelial
cell proliferation, we investigated whether 6-ME could
inhibit other angiogenic responses of endothelial cells.
Indeed, angiogenesis is a complex process that involves
many partial steps such as production of proteolytic
enzymes that degrade the basement membrane, migra-
tion, proliferation, tube formation, generation of base-
ment membrane and recruitment of mural cells [26].
Several of these processes including tube formation can
be reconstituted in vitro using 3D cultures on Matrigel,
a basement membrane matrix from Engelbreth-Holm-
Swarm mouse tumors [28]. Indeed, human umbilical
vein endothelial cells form capillary-like structures on
Matrigel substrates. 6-ME, even at high doses, did not
exhibit any effect on the Matrigel assay. Migration is a
critical angiogenic response of ECs allowing them to
reach the membrane breach for invasion to the extracel-
lular space. VEGF is a prime regulator of EC migration.
VEGF-induced phosphorylation of Tyr1214 of VEGFR2
activates SAPK2/p38 [12] leading to VEGF-induced actin
reorganization and migration of ECs via phosphorylation
of heat-shock protein-27 (HSP27) [29] and LIM-kinase 1
(LIMK1) [6]. 6-ME did not exhibit any inhibitory effect
on VEGF-induced migration of ECs and did not inhibit
phosphorylation of p38 by the VEGF/VEGFR2 complex.
It appeared, therefore, that the main target of 6-ME
was EC proliferation. Interestingly, 6-ME inhibited both
VEGF- and FGF2-induced EC proliferation. In humans,
upon VEGF-A binding, phosphorylation of VEGFR2
on Tyr1175 leads to recruitment of PLCγ, which in
turn, via activation of PKC, phosphorylates MEK1/2 and
eventually mitogen-activated protein kinase (MAPK)/
extracellular-signal-regulated kinase-1/2 (ERK1/2) lead-
ing to proliferation of ECs [5]. Such activation of MAPKs
by VEGF is different from classic Ras-Raf-MEK-MAPK
pathway, which is used by most receptor tyrosine kinases
including FGF2 [13,14]. Nevertheless, it has been shown
that PKC-dependent activation of MEK1/2 requires aRas-Raf complex formation [30]. This PKC/Ras-Raf func-
tional interaction is not so well understood and might
include other hitherto unidentified components. PKC
and Ras-Raf are the points where the VEGF and FGF2
cascades arrive just before the first downstream common
effector, MEK1/2, as far as activation of MAPK is con-
cerned. The finding that 6-ME inhibits both the VEGF
and FGF2-induced EC proliferation as well as MEK1/2
phosphorylation suggests that the PKC/Ras-Raf inter-
action is the only point where 6-ME could target
both pathways with one activity. Otherwise, 6-ME would
need two activities targeting two different components
upstream to MEK1/2, one for each pathway. This is a
point that requires future attention.
Thus, inhibition of MEK1/2 and consequently ERK1/2
phophorylation was the sole cardinal effect of 6-ME on
the signaling cascade of VEGF in HUVECs; activation of
AKT and P38 were unaffected. This mechanism is strik-
ingly different compared to the effects of the flavonoid
luteolin on VEGF signaling in HUVECs [10]. Luteolin,
inhibited the PI3K/AKT pathway abolishing downstream
survival signals, but also enhanced the pro-apoptotic
MKK3/MKK6/p38 pathway of VEGF eliciting a strong
apoptotic effect in ECs. Regarding the anti-mitotic activ-
ity, luteolin inhibited VEGF-induced phosphorylation
of p70 S6K, a downstream effector of PI3K responsible
for G1 progression. Surprisingly, luteolin did not affect
VEGF-induced phosphorylation of ERK1/2 MAP kinases.
Thus, two representatives (luteolin and 6-ME) of closely
related isomeric compound classes (flavonoids and Iso-
flavonoids) exhibited entirely different molecular targets
concerning the VEGF-dependent signaling cascades in
HUVECs. Perhaps, the fact that these compounds are
competitive inhibitors of ATP binding [31] allows them
to target a variety of tyrosine and serine kinases [31,32].
6-ME was eventually tested in animal models. For this
purpose, we used a murine tumor xenograft model util-
izing A-431 cells, a human epidermoid carcinoma cell
line that produces VEGF [19]. 6-ME administered orally
in this model was devoid of any effect. The experimental
and control tumors did not show any difference in their
average volumes). We postulated that low bioavailability
is the reason for the lack of effect. Indeed, estimation of
the free, conjugated and total amounts of 6-ME in the
plasma of the mice revealed that the maximum concen-
tration achieved was 1.23 μM, a value below the in vitro
IC50 of the compound (around 5-10μM). Several factors
contribute to the bioavailability including absorption,
distribution, metabolism and elimination. There are no
extensive studies on these issues concerning isoflavo-
noids. However, the studies so far [20,21] anticipate
that isoflavones are rather poorly bioavailable. In a
study in human adults, consumption of 50 mg of iso-
flavones per day yielded plasma concentrations ranging
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food rich in soy or red clover only traces of 6-ME were
detected in soy human urine [24]. The low biovailability
excludes any significant contribution of 6-ME to the pro-
tective function of plant-based diets on cancer incidence.
However, biovailable analogs of 6-ME could be used
therapeutically to target tumor angiogenesis. Alternatively,
6-ME could be loaded in nanoparticles targeted to ECs,
where they could be endocytosed and eventually release
their cargo. Indeed, when injected directly to the xeno-
graft tumors, to bypass its low biovailability, 6-ME sup-
pressed tumor vascularization resulting to a statistically
significant decrease in the volumes of murine A-431
xenograft tumors. Thus, 6-ME acquires the potential to
be developed into a therapeutic anti-cancer agent. In this
capacity, 6-ME or 6-ME analogs have two very important
and unique properties. 6-ME inhibits only VEGF-induced
MEK1/2 activation inhibiting exclusively EC proliferation
without influencing VEGF-induced survival. Thus, one
can anticipate that it targets only dividing ECs in the
vicinity of tumors, without affecting the survival of the
quiescent normal endothelium. Moreover, it inhibits also
FGF2, which an alternative angiogenic factor expressed
when ECs develop resistance (Angiogenic Redundancy)
[33] against current anti-VEGF treatments [34]. This is a
very important issue in the anti-VEGF treatments.
In conclusion, 6-ME, a natural isoflavone found also in
humans, inhibits VEGF- and FGF2-induced proliferation
of ECs. The molecular target of 6-ME is upstream of
MEK1/2 inhibiting phosphorylation of MEK1/2 and
ERK1/2 kinases that are important components of the
mitogenic MAPK pathway. 6-ME does not affect the
PI3K/AKt pathway, thereby not affecting VEGF-dependent
survival of ECs. Oral administration in mice fails to
achieve sufficient plasma concentrations to inhibit neovas-
cularization and growth of xenograft tumors in mice.
However, direct injections of 6-ME to the xenograft
tumors, to bypass its low biovailability, suppress tumor
vascularization resulting to a statistically significant de-
crease in the volumes of murine A-431 xenograft tumors.
Concomitant inhibition of VEGF- and FGF2-induced EC
proliferation and targeting only dividing ECs without
affecting the survival of ECs are two properties rendering
6-ME as an attractive molecule for the development of a
novel anti-angiogenic intervention in cancer treatment.Additional file
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